Drug Trial Radar · NCT02528253
A Phase 3 Study of Tanezumab for Chronic Low Back Pain
Last checked: Nov 19, 2026Latest source record: Feb 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,832
Actual
Start
Aug 18, 2015
Primary completion
Oct 17, 2017
Study completion Dec 20, 2018
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Aug 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks). The primary objective of this study is to evaluate the effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. Secondary objectives are to evaluate the long-term safety and effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. In addition, the study will evaluate the effectiveness and long term safety profile of tanezumab treatment for chronic low back pain compared to tramadol Prolonged Release (PR), a medication commonly utilized for the treatment of chronic low back pain.
Conditions
- Low Back Pain
Interventions
Placebo to Week 16; tanezumab 5mg SCBiological
Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
Placebo to Week 16, tanezumab 10 mg SCBiological
Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
Tanezumab 5 mg SCBiological
Tanezumab 5 mg SC
Tanezumab 10 mg SCBiological
Tanezumab 10 mg SC
Tramadol PR oralBiological
Tramadol PR oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Average Low Back Pain Intensity (LBPI) Score for Tanezumab Versus (Vs) Placebo at Week 16Time frame: Baseline, Week 16
Locations
262 sites in 9 countries. Site status is shown where the registry gives one.
Central Alabama Research
Birmingham, Alabama
Cahaba Research
Birmingham, Alabama
Alabama Clinical Research, LLC
Mobile, Alabama
Alabama Orthopaedic Clinic, P.C.
Mobile, Alabama
Coastal Clinical Research
Mobile, Alabama
Horizon Research Partners, LLC
Mobile, Alabama
The Center for Clinical Trials, Inc.
Saraland, Alabama
Ferguson Family Medicine
Mesa, Arizona
The Pain Center of Arizona
Phoenix, Arizona
Arizona Research Center
Phoenix, Arizona
Valley Pain Consultants
Scottsdale, Arizona
KLR Business Group dba Arkansas Clinical Research
Little Rock, Arkansas
Lynn Institute of the Ozarks
Little Rock, Arkansas
Primary Care of Arkansas, P.A.
Little Rock, Arkansas
Anaheim Clinical Trials, LLC
Anaheim, California
Core Healthcare Group
Cerritos, California
eStudySite
Chula Vista, California
Triwest Research Associates, LLC
El Cajon, California
Research Center of Fresno, Inc.
Fresno, California
Neuro-Pain Medical Center
Fresno, California
Valley Research-Trials
Fresno, California
Collaborative Neuroscience Network, LLC.
Garden Grove, California
eStudySite
La Mesa, California
Collaborative Neuroscience Network, LLC.
Long Beach, California
University of Southern California
Los Angeles, California
USC IDS Pharmacy
Los Angeles, California
Catalina Research Institute, LLC
Montclair, California
Providence Clinical Research
North Hollywood, California
Northern California Research
Sacramento, California
Artemis Institute for Clinical Research
San Diego, California
Encompass Clinical Research
Spring Valley, California
Bayview Research Group
Valley Village, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Elite Clinical Trials, Inc.
Wildomar, California
Alpine Clinical Research Center
Boulder, Colorado
Mountain View Clinical Research, Inc.
Denver, Colorado
Mountain View Clinical Research, Inc
Denver, Colorado
New England Research Associates, LLC
Bridgeport, Connecticut
My Health 1st Urgent Care
Milford, Connecticut
Stamford Therapeutics Consortium
Stamford, Connecticut
Showing 40 of 262 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.